130 search results for: Burden of Disease
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.
ADVENT On Air | Best Practice for CSU - Perspectives from Allergy and Dermatology
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
Coughing, Choking, Wheezing, Itching, Sneezing: Understanding the Connection Between Atopic Diseases Through a Case-Based Panel of Expert Nurse Practitioners
Join leading experts Miguel Lanz, Lakshi Aldredge, Angela Bretton, and Hilary Ugras in an engaging case-based discussion that explores the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews emerging evidence linking atopic dermatitis not only to atopic comorbidities but to a range of non-atopic systemic diseases, including mental health disorders, neurodevelopmental conditions and impaired bone health.
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
World Anosmia Day 2026
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.
ADVENT at ATS 2026
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.
Managing the Risk of Fibrostenosis in EoE
Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.
